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Abstract
In 2009, the revised United States Preventive Services Task Force (USPSTF) guideli-
nes recommended against routine screening mammography for women age 40-
49 years and against teaching self-breast examinations (SBE). The aim of this study
was to analyze whether breast cancer method of presentation changed following the
2009 USPSTF screening recommendations in a large Michigan cohort. Data were col-
lected on women with newly diagnosed stage 0-III breast cancer participating in the
Michigan Breast Oncology Quality Initiative (MiBOQI) registry at 25 statewide insti-
tutions from 2006 to 2015. Data included method of detection, cancer stage, treat-
ment type, and patient demographics. In all, 30 008 women with breast cancer
detected via mammogram or palpation with an average age of 60.1 years were
included. 38% of invasive cancers were identified by palpation. Presentation with pal-
pable findings decreased slightly over time, from 34.6% in 2006 to 28.9% in 2015
(P < .001). Over the 9-year period, there was no statistically significant change in rate
of palpation-detected tumors for women age <50 years or ≥50 years (P = .27, .30,
respectively). Younger women were more likely to present with palpable tumors com-
pared to older women in a statewide registry. This rate did not increase following
publication of the 2009 USPSTF breast cancer screening recommendations.
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1 | INTRODUCTION
Since 1990, mortality rates due to breast cancer have been decreas-
ing by 2.3% per year overall and by 3.3% for women 40-50 years of
age.1 The decrease in mortality has been attributed to early detec-
tion via screening mammography and improvements in systemic
therapy.2 A significant benefit of mammography is the ability to
detect cancer at an earlier stage, which may be a contributing factor
to increased survival rates and decreased breast cancer recur-
rence.3,4 A reduction in breast cancer mortality rates due to teaching
breast self-exam has not been confirmed. However, Mathis et al5
reported that a significant number of breast tumors (43%) were ini-
tially detected through palpation by either the patient or clinician.
In 2009, the United States Preventive Services Task Force
(USPSTF) revised their breast cancer screening recommendations.6
The most significant change was the recommendation against
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routine screening mammography for women 40-49 years of age,
which received a C grade. In addition, a recommendation against
teaching self-breast examinations (SBE) was established in response
to randomized studies indicating that teaching self-breast examina-
tions had no impact on breast-cancer-related mortality and was
associated with an increased risk of undergoing a benign breast
biopsy.7 The recently published update to the recommendations
again confirmed that routine screening mammography should not be
performed in this population, but rather the decision should be made
on an individual basis.8
The aim of this study was to analyze the method of breast can-
cer presentation before and after the USPSTF recommendations
were released in 2009 for women seen at hospitals participating in
the Michigan Breast Oncology Quality Initiative (MiBOQI) from 2006
to 2015.
2 | METHODS
Michigan breast oncology quality initiative (MiBOQI) is a multi-insti-
tution, statewide breast cancer registry that is a collaborative quality
initiative sponsored by Blue Cross Blue Shield of Michigan/Blue Care
Network.9,10 The MiBOQI registry contains over 300 data elements
encompassing demographics, diagnosis, staging, and treatment; it
does not include data prior to diagnosis. Follow-up data are obtained
4, 9, 18, and 30 months after initial diagnosis.
We analyzed data for women diagnosed with stage 0-III breast
cancer between 2006 and 2015 from 25 medical institutions with at
least 270 days follow-up (to allow capture of chemotherapy and
radiotherapy). Patients with missing data in any of the following
fields were excluded from analysis: (i) Age at diagnosis, (ii) Breast
cancer presentation, and (iii) TNM Stage (Figure 1). The breast can-
cer presentation was classified into 3 groups: (i) Mammography, (ii)
Palpation during breast examination (either self or clinician) and, (iii)
Other. The “Other” presentations category included bloody nipple
discharge, inverted nipple, axillary mass, or breast pain/discomfort.
Only women whose cancers were identified through either palpation
or mammography were included in the analysis.
All data were de-identified prior to analysis. This study was
approved by the Institutional Review Board at Grand Valley State
University, Allendale, Michigan (Approval #175143-1). The statistical
software packages SAS and R were used to analyze and compare
method of detection with categorical variables (ie, TNM staging and
surgical management) and continuous variables (ie, age at the time
of initial diagnosis). Chi-square tests and 2 sample t tests were used,
respectively. A statistically significant P value was considered to be
P < .05.
3 | RESULTS
3.1 | Disease presentation
In all, 30 008 women met study criteria. Patient demographic and
staging data are summarized in Table 1. The average age at of diagno-
sis was 60.1 years [standard deviation (SD) 12.9]. DCIS without inva-
sive breast cancer was diagnosed in 6036 patients. In the 23 972
patients in the invasive cohort, 14 929 (62.3%) had mammographically
detected tumors, and 9041 (37.7%) presented with a palpable tumor.
Of the patients with palpable tumors, 87.0% were detected through
self-examination, 8.4% were detected by clinician examination, and
4.6% had other presenting clinical symptoms (Figure 1).
Presentation with palpable findings decreased slightly over time
in the entire cohort, from 34.6% in 2006 to 28.9% in 2015
(P < .001, Figure 2). For women under age 50 years, the rate of can-
cer detection by palpation decreased from 67% in 2006 to 54% in
2015, which was not a statistically significant decrease (P = .27; Fig-
ure 3). For women age 50 years and over, the rate remained essen-
tially stable, and was 29% in 2006 and 30% in 2015 (P = .30,
Figure 3). Across the 25 participating MiBOQI sites, there was a sta-
tistically significant (P < .001) variation in rates of palpation-detected
tumors (Figure 4), which varied from 24% to 45%.
3.2 | Associations between disease presentation
and clinicopathologic characteristics
Compared to patients with invasive cancer who had mammographi-
cally detected tumors, patients with a palpable tumor at presentation
were more likely to be younger, black race, and insured by commer-
cial (non-Medicare) plans or Medicaid. They are also more likely to
have higher stage disease, higher tumor grade, ductal histology, lack
ER and PR expression, and have HER2 overexpression or amplifica-
tion (Table 2). On multivariate analysis, all of these factors remained
statistically significant, with the exception of race and HER2 overex-
pression.
When specifically examining patients under age 50 years, com-
pared to those with mammographically detected tumors, patients
with a palpable tumor at presentation were more likely to be black
race, insured by Medicaid, have higher clinical stage disease, and
have tumors with higher grade, ER and PR negativity, and HER2
overexpression P < .001 (Table 3). On multivariate analysis, only
higher clinical stage remained statistically significant.
F IGURE 1 Exclusion criteria diagram [Color figure can be viewed
at wileyonlinelibrary.com]
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Comparison of patients age 50 years and older with a palpable
tumor vs a mammographically detected tumor at presentation
yielded similar results. Patients with palpable tumors were more
likely to be black race, insured by Medicaid, have higher clinical
stage disease, and have tumors with higher grade, ER and PR





N = 23 972 DCIS N = 6036
Age at diagnosis, years
<50 5365 (22%) 1375 (23%)
≥50 18 596 (78%) 4661 (77%)
Missing 11 6
Race
Black 3113 (13%) 872 (14%)
White 19 414 (81%) 4770 (79%)
Other 1445 (6%) 400 (7%)
Insurance payor
Commercial 10 511 (55%) 2933 (61%)
Government 116 (1%) 18 (0%)
Medicaid 1154 (6%) 203 (4%)
Medicare 7282 (38%) 1635 (34%)
Other 39 (0%) 17 (0%)
Uninsured 78 (0%) 9 (0%)
Missing 4792 1227
Clinical stage
Stage 0 N/a 6042 (100%)
Stage I 13 722 (57%) N/a
Stage II 7840 (33%) N/a
Stage III 2410 (10%) N/a
Histologic grade
Grade 1 6069 (26%) N/a
Grade 2 10 106 (44%) N/a
Grade 3 7004 (30%) N/a
Other 25 (0%) N/a
Missing 768 N/a
Surgery
BCS 15 268 (64%) 4409 (73%)
Mastectomy 8285 (35%) 1573 (26%)
Other 419 (2%) 60 (1%)
Estrogen receptor positive
No 4243 (18%) N/a
Yes 19 628 (82%) N/a
Missing 101 N/a
Progesterone receptor positive
No 6452 (27%) N/a
Yes 17 364 (73%) N/a
Missing 156 N/a
HER2 positive
No 20 728 (87%) N/a







N = 23 972 DCIS N = 6036
Triple negative
No 22 118 (93%) N/a
Yes 1675 (7%) N/a
Missing 179 N/a
N/a, not applicable.
F IGURE 2 Percent of patients with tumors diagnosed by
palpation, by year
F IGURE 3 Percent of patients with tumors diagnosed by
palpation age <50, ≥ 50 by year
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negativity, and HER2 overexpression P < .001 (Table 3). On multi-
variate analysis, only insurance payor, stage, surgery type, and PR
negativity remained statistically significant.
On univariate analysis, comparing patients under age 50 years
with older women, there were associations between method of
detection of the tumor and insurance payor, clinical stage, type of
surgery, and PR overexpression (Table 3). The association between
other factors, including race, tumor grade, and histology, and method
of detection of the tumor did not differ between the age groups.
4 | DISCUSSION
In this contemporary cohort of 30 008 breast cancer patients,
approximately one-third of patients presented with a palpable tumor,
and this rate decreased slightly over time from 2006 to 2015.
Women with palpable cancers were younger and presented with
more advanced tumor stages and more aggressive tumor profiles
than those with mammography-detected cancers. Our results are
concordant with prior reports in the literature.5
F IGURE 4 Percent of patients with tumors diagnosed by
palpation, by michigan breast oncology quality initiative participating
site
TABLE 2 Multivariate analysis of associations between demographic and clinicopathologic characteristics and method of breast cancer
detection
Characteristic Palpation N = 9041 Mammogram N = 14 929 Univariate P value Multivariate P value
Age at diagnosis, years
<50 3197 (35%) 2168 (15%) <.001 <.001
≥50 5840 (65%) 12 754 (85%)
Missing 4 7
Race
Black 1408 (16%) 1705 (11%) <.001 .2980
White 7032 (78%) 12 380 (83%)
Other 601 (7%) 844 (6%)
Insurance payor
Commercial 4232 (58%) 6279 (53%) <.001 <.001
Government 40 (1%) 76 (1%)
Medicaid 682 (9%) 472 (4%)
Medicare 2228 (31%) 5052 (42%)
Other 12 (0%) 27 (0%)
Uninsured 52 (1%) 26 (0%)
Missing 1795 2997.00
Clinical stage
Stage I 2782 (31%) 10 940 (73%) <.001 <.001
Stage II 4556 (50%) 3282 (22%)
Stage III 1703 (19%) 707 (5%)
Tumor grade
Grade 1 1325 (15%) 4744 (33%) <.001 <.001
Grade 2 3518 (40%) 6588 (46%)
(Continues)
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TABLE 2 (Continued)
Characteristic Palpation N = 9041 Mammogram N = 14 929 Univariate P value Multivariate P value
Grade 3 3915 (45%) 3088 (21%)
Other 9 (0%) 15 (0%)
Missing 274 494
Histology
Invasive ductal 7711 (85%) 12 432 (83%) <.001 .0272
Invasive ductal and lobular 173 (2%) 331 (2%)
Invasive lobular 882 (10%) 1569 (11%)
Other 275 (3%) 597 (4%)
Missing
Estrogen receptor positive
No 2338 (26%) 1903 (13%) <.001 <.001
Yes 6664 (74%) 12 964 (87%)
Missing 39 62
Progesterone receptor positive
No 3183 (35%) 3267 (22%) <.001 .0064
Yes 5810 (65%) 11 554 (78%)
Missing 48 108
HER2 positive
No 7469 (83%) 13 258 (89%) <.001 .3739
Yes 1549 (17%) 1656 (11%)
Missing 9 3
Triple negative 48 108
No 8217 (91%) 13 899 (94%) <.001 N/a
Yes 765 (9%) 910 (6%)
Missing 23 15
Surgery
BCS 4449 (49%) 10 817 (72%) <.001 <.001
Mastectomy 4340 (48%) 3945 (26%)
Other 252 (3%) 167 (1%)
TABLE 3 Univariate analysis of associations between demographic and clinicopathologic characteristics and patient age at time of breast
cancer diagnosis
Characteristic
Patients 49 & Under
P value











N = 12 754
Race .546
Black 537 (17%) 259 (12%) <.001 870 (15%) 1444 (11%) <.001
White 2398 (75%) 1735 (80%) 4631 (79%) 10 640 (83%)
Other 262 (8%) 174 (8%) 339 (6%) 670 (5%)
Insurance payor
Commercial 2055 (82%) 1474 (87%) <.001 2175 (46%) 4802 (47%) <.001 .027
Government 18 (1%) 16 (1%) 22 (0%) 60 (1%)
Medicaid 334 (13%) 152 (9%) 348 (7%) 319 (3%)
Medicare 68 (3%) 48 (3%) 2158 (46%) 5004 (49%)
Other 7 (0%) 7 (0%) 5 (0%) 20 (0%)
(Continues)
734 | CAUGHRAN ET AL.
The impact the 2009 USPSTF screening recommendations have
had on cancer presentation is unknown. A review of screening mam-
mography utilization by Sharpe et al11 in the Medicare population
noted a decrease in 4.3% in 2010 in this older population after see-
ing annual growth of 0.5% prior to the 2009 recommendations. In
contrast, using claims data, a smaller decrease in screening
TABLE 3 (Continued)
Characteristic
Patients 49 & Under
P value











N = 12 754
Uninsured 27 (1%) 5 (0%) 25 (1%) 21 (0%)
Missing 688 466 1107 2528
Clinical stage
Stage I 963 (30%) 1417 (65%) <.001 1816 (31%) 9518 (75%) <.001 <.001
Stage II 1631 (51%) 594 (27%) 2924 (50%) 2686 (21%)
Stage III 603 (19%) 157 (7%) 1100 (19%) 550 (4%)
Tumor grade
Grade 1 390 (13%) 619 (30%) <.001 934 (17%) 4124 (33%) .766
Grade 2 1137 (37%) 935 (45%) 2379 (42%) 5648 (46%)
Grade 3 1574 (51%) 535 (26%) 2340 (41%) 2553 (21%)
Other 3 (0%) 3 (0%) 6 (0%) 12 (0%)
Missing 93 76 181 417
Invasive ductal 2854 (89%) 1861 (86%) <.001 4854 (83%) 10 566 (83%) <.001 .162
Invasive ductal and lobular 41 (1%) 44 (2%) 132 (2%) 287 (2%)
Invasive lobular 222 (7%) 180 (8%) 660 (11%) 1388 (11%)
Other histology 80 (3%) 83 (4%) 194 (3%) 513 (4%)
ER positive
No 922 (29%) 280 (13%) <.001 1414 (24%) 1622 <.001 .257
Yes 2260 (71%) 1873 (87%) 4402 (76%) 11 085 (87%)
Missing 15 15 24 47
PR positive
No 1124 (35%) 380 (18%) <.001 2058 (35%) 2886 (23%) <.001 .005
Yes 2057 (65%) 1763 (82%) 3750 (65%) 9785 (77%)
Missing 16 25 32 83
HER2 positive
No 2532 (79%) 1850 (85%) <.001 4934 (85%) 11 403 (89%) <.001 .349
Yes 656 (21%) 315 (15%) 892 (15%) 1339 (11%)
Missing 9 3 14 12
Triple negative
No 2802 (88%) 1941 (91%) .002 5411 (93%) 11 953 (94%) .002 .9250
Yes 375 (12%) 200 (9%) 390 (65%) 708 (6%)
Missing 20 27 39 93
Surgery
BCS 1347 (42%) 1170 (54%) <.001 3099 (53%) 9642 (76%) <.001 <.0010
Mastectomy 1796 (56%) 979 (45%) 2543 (44%) 2966 (23%) .925
Other 54 (2%) 19 (1%) 198 (3%) 146 (1%) .349
Receipt of chemo
No 497 (17%) 819 (45%) <.001 1865 (38%) 6785 (66%) <.001 .130
Yes 2393 (83%) 1021 (55%) 3009 (62%) 3511 (34%)
Missing 307 328 966 2458
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mammography use of 1.2% was identified in a cohort of insured
women under the age of 50 years.12 In our MiBOQI cohort of
women under 50 years, no compensatory increase in palpable
tumors was noted after the 2009 recommendations, but rather the
rate remained relatively stable. The reason for this finding is uncer-
tain, but likely multifactorial. One potential explanation is that
screening mammography rates may have remained relatively
unchanged despite the 2009 guidelines. In particular, the enactment
of the Affordable Care Act may have enabled more women of all
ages to undergo screening mammography, thereby offsetting
changes related to less aggressive screening recommendations. How-
ever, as noted below, we are unable to assess this possibility in our
cohort because of limitations of the MiBOQI Registry. If screening
rates did in fact decline, then the inability to diagnosis more of the
indolent tumors was not seen, as demonstrated by a compensatory
increase in palpable method of detection, within the time frame of
the study.
Our study only included women with a breast cancer diagnosis
and did not include the general screening population, so no compar-
isons can be made regarding screening efficacy. Data collected rep-
resent only a snapshot of each patient’s presentation without
information on previous screening practices. Conflicting recommen-
dations have been made regarding the age at which to initiate
screening mammography. Work by Hayse et al13, suggest that
screen-detected tumors have more indolent biology than cancers
with a palpable presentation. In our cohort, palpable tumors were
more likely to be ER negative or HER2 positive amongst women of
all age groups. However, information regarding whether these
tumors represent interval cancers between mammograms or if they
were mammographically occult was not captured in the Registry. In
a study by Bellio et al14, 20% of patients in a mammographic screen-
ing program presented with interval breast cancers, and these
tumors had worse prognostic features and clinical outcomes than
screen-detected tumors. These findings further strengthen the argu-
ment that women and clinicians should not rely on mammography
alone for breast cancer detection. A considerable strength of this
analysis is the large size of the cohort, which is derived from prac-
tices that are heterogeneous, and reflect community- and academic-
based practices, urban, suburban, and rural areas, and communities
with low and high socioeconomic status. In this statewide registry,
we demonstrate that that there is considerable variability across hos-
pital systems in method of breast cancer presentation. This
variability could be due to differences in practice patterns across the
state, or could reflect differences in patient mix at different institu-
tions.
During this time period regardless of healthcare policy changes,
22.3% of the cancers in this cohort were in women under the age of
50 years, and these women presented with palpable tumors at a
much greater frequency than those over the age of 50 years. A
higher stage of presentation, more aggressive biology, and more
extensive surgical management then follows in younger women.
Clinicians should consider these data when determining the impact
screening recommendations will have on their patient population.
5 | CONCLUSION
This cohort demonstrates no increase in the diagnosis of breast can-
cer because of presentation with palpable findings following the
USPSTF 2009 recommendations based on comparison of rates for
3 years before and 6 years after their publication. These multi-insti-
tutional data derived from a large Registry cohort provide a robust
view of the clinical presentation of breast cancer in a modern cohort.
Women with breast cancer detected by mammography presented
with earlier stage disease in all age groups and often underwent less
aggressive local therapy. Women under the age of 50 years, who
accounted for almost one-quarter of the Registry cohort, were more
likely to present with a palpable mass although this rate did not
increase following the 2009 recommendations. These findings under-
score the importance of recognizing and thoroughly evaluating of
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